ArticleFrontiers in oncology2026
Precision medicine directed therapy enabling long-term survival in medulloblastoma: a case report.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02162732 (Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Subgroup-SHH of medulloblastoma (MB) is primarily found in children, with an increased propensity for metastatic presentation that contributes to its poor prognosis. Current therapy approaches may include surgery, radiation, systematic chemotherapy, and autologous stem cell transplant (ASCT). At relapse, patients may receive additional chemotherapy and radiation if possible. The outcome for relapsed patients is 10-30% long term survival. Herein we present a case of a 6-year-old male with a pathologically confirmed diagnosis of subgroup-SHH MB, who was treated with upfront surgical resections, high-dose chemotherapy, and ASCT. Nine months after completion of upfront therapy, the subject relapsed. Subsequently, he was enrolled onto NMTRC009 (NCT02162732) and underwent biopsy with genomic sequencing (DNA whole exome and RNA transcriptome). A molecular tumor board, using precision medicine analysis, recommended vorinostat, vismodegib, curcumin, and palbociclib as targeted therapy. This therapy resulted in a complete tumor response and long-term survival. A cell line was derived from the subject's tumor and used for
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.